Anti-Alpha-Synuclein Formulations for Stable Low-Viscosity IV Dosing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack reliable ways to confirm target engagement of monoclonal antibodies with low-abundance pathological alpha synuclein species in CSF and plasma, hindering the establishment of effective dosing regimens for treating synucleinopathies.
Innovation Solution
Development of specific dosing regimens for monoclonal anti-alpha synuclein antibodies based on complex modeling, ensuring target engagement with pathological alpha synuclein species in CSF, using stable and low viscosity liquid pharmaceutical compositions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If monoclonal antibodies are used to treat synucleinopathies, then therapeutic efficacy is improved, but formulation stability and viscosity control become challenging
Solution Approach 1:
The patent applies parameter changes by optimizing formulation conditions including pH (5.0-7.0), temperature (2-8°C storage), ionic strength, and excipient concentrations to maintain antibody stability while achieving low viscosity. The formulation parameters are specifically tuned to prevent aggregation and degradation of the monoclonal antibody.
Solution Approach 2:
The patent uses composite materials by combining the monoclonal antibody with multiple excipients including buffering agents (sodium phosphate, histidine), tonicity agents (sodium chloride, mannitol), and surfactants (polysorbate 20, polysorbate 80) to create a stable liquid formulation that maintains therapeutic efficacy while ensuring physical and chemical stability.
2Reliability
If monoclonal antibodies are formulated for intravenous administration, then patient safety is improved, but viscosity must be controlled for injectability
Solution Approach 1:
The patent controls viscosity by adjusting formulation parameters including protein concentration (10-100 mg/mL), pH, ionic strength, and temperature. The formulation is designed to maintain viscosity below 100 cP at therapeutic concentrations to ensure ease of intravenous administration while maintaining patient safety.
3Reliability
If dosing regimens are established based on target engagement modeling, then treatment effectiveness is improved, but complexity of dosing determination increases
Solution Approach 1:
The patent applies preliminary action by performing complex pharmacokinetic/pharmacodynamic modeling and target engagement studies during the drug development phase to establish dosing regimens before clinical use. This preliminary work determines optimal dosing parameters including dose amount, frequency, and duration based on in vitro and in vivo data.
Solution Approach 2:
The patent uses feedback by incorporating target engagement measurements and pharmacokinetic monitoring to refine and optimize dosing regimens. The modeling approach integrates experimental data on antibody binding to alpha-synuclein aggregates with pharmacokinetic parameters to determine dosing strategies that achieve therapeutic targets.
Data Source
AI summary
The present invention relates to stable and low viscosity liquid pharmaceutical compositions comprising antibodies binding to human alpha synuclein and to methods for use of antibodies binding to human alpha synuclein for treating synucleinopathies or prodromal synucleinopathy, incl. suitable doses and/or dosing regimens. These antibodies for use in treatment of synucleinopathies or prodromal synucleinopathy may be formulated in the stable and low viscosity liquid pharmaceutical compositions of the invention.